BIO-TECHNE CORPORATION

(TECH)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
375.15 USD   -2.04%
08/05Stephens Lowers Bio-Techne Corp Price Target to $480 From $500, Maintains Overweight Rating
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05BIO TECHNE : ANNOUNCES CEO TRANSITION PLAN - Form 8-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
387.01(c) 391.85(c) 390.9(c) 382.97(c) 375.15 Last
234 682 279 169 448 893 177 498 161 758 Volume
+0.98% +1.25% -0.24% -2.03% -2.04% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 108 M - -
Net income 2022 270 M - -
Net cash position 2022 129 M - -
P/E ratio 2022 58,5x
Yield 2022 0,33%
Sales 2023 1 239 M - -
Net income 2023 268 M - -
Net cash position 2023 168 M - -
P/E ratio 2023 58,1x
Yield 2023 0,34%
Capitalization 14 718 M 14 718 M -
EV / Sales 2022 13,2x
EV / Sales 2023 11,7x
Nbr of Employees 3 000
Free-Float 99,3%
More Financials
Company
More about the company
Ratings of Bio-Techne Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIO-TECHNE CORPORATION
08/05Stephens Lowers Bio-Techne Corp Price Target to $480 From $500, Maintains Overweight Ra..
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05BIO TECHNE : ANNOUNCES CEO TRANSITION PLAN - Form 8-K
PU
08/05BIO-TECHNE CORP : Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
08/04TRANSCRIPT : Bio-Techne Corporation, Q4 2022 Earnings Call, Aug 04, 2022
CI
08/04Bio-Techne Fiscal Q4 Adjusted Earnings, Sales Rise; CEO Chuck Kummeth to Retire in 2024
MT
08/04Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q4 Revenue $288.2M
MT
08/04Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q4 EPS $2.05
MT
08/04BIO-TECHNE CORP : Results of Operations and Financial Condition, Other Events, Financial S..
AQ
08/04Bio-techne declares dividend
PR
08/04Bio-techne announces ceo transition plan
PR
08/04Bio-techne releases fourth quarter fiscal 2022 results
PR
08/04Bio-Techne Corporation Reports Earnings Results for the Full Year Ended June 30, 2022
CI
08/04Bio-Techne Corporation Reports Earnings Results for the Fourth Quarter Ended June 30, 2..
CI
08/04Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable ..
CI
More news
News in other languages on BIO-TECHNE CORPORATION
08/04Hausse du bénéfice ajusté et des ventes de Bio-Techne au quatrième trimestre fiscal ; l..
08/04Earnings Flash (TECH) BIO-TECHNE CORPORATION annonce un chiffre d'affaires de 288,2 mil..
08/04Bio-Techne Corporation annonce ses résultats pour l'année complète se terminant le 30 j..
08/04Bio-Techne Corporation annonce ses résultats pour le quatrième trimestre clos le 30 jui..
08/04Bio-Techne Corporation annonce un dividende pour le trimestre se terminant le 30 juin 2..
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 382,97 $
Average target price 473,91 $
Spread / Average Target 23,7%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel CFO & Principal Accounting Officer
Robert V. Baumgartner Chairman
Robert Monroe Chief Medical Officer
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION-25.97%15 025
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.80%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235